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Relative to several other toll-like receptor (TLR) agonists, we found polyinosinic:polycytidylic acid (poly IC) to be the most effective adjuvant for Th1 CD4+ T cell responses to a
dendritic cell (DC)–targeted HIV gag protein vaccine in mice. To identify mechanisms for
adjuvant action in the intact animal and the polyclonal T cell repertoire, we found poly IC
to be the most effective inducer of type I interferon (IFN), which was produced by
DEC-205+ DCs, monocytes, and stromal cells. Antibody blocking or deletion of type I IFN
receptor showed that IFN was essential for DC maturation and development of CD4+
immunity. The IFN-AR receptor was directly required for DCs to respond to poly IC. STAT 1
was also essential, in keeping with the type I IFN requirement, but not type II IFN or IL-12
p40. Induction of type I IFN was mda5 dependent, but DCs additionally used TLR3. In bone
marrow chimeras, radioresistant and, likely, nonhematopoietic cells were the main source
of IFN, but mda5 was required in both marrow–derived and radioresistant host cells for
adaptive responses. Therefore, the adjuvant action of poly IC requires a widespread innate
type I IFN response that directly links antigen presentation by DCs to adaptive immunity.
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Vaccines induce protective immunity against
numerous infectious diseases. However, current vaccines have limited efficacy against challenging infections like tuberculosis, malaria, and
HIV, where Th1-type T cell immunity likely has
a potentially important role (Seder and Mascola,
2003). Proteins represent a potential route to
safe new generation vaccines (Ulmer et al.,
2006), but, typically, these are poorly immunogenic for T cells when administered alone.
Therefore, special attention is being given to
additional adjuvants or enhancers of immunity.
Adjuvants activate innate immunity and, in particular, the maturation of antigen-presenting
immunostimulatory DCs (Pulendran and Ahmed,
2006; Kool et al., 2008). To understand adjuvant action, and to identify optimal ones, it is
necessary to move beyond the current focus on
in vitro assays and selected monoclonal or TCR
transgenic T cells to the intact animal and patient. This avenue of research should also help
to identify mechanisms that link innate responses
to adaptive immunity in vivo.
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Adjuvants can stimulate innate immunity
by interacting with specialized pattern recognition receptors (PRRs), including Toll-like receptors (TLRs; Akira et al., 2006; Kawai and
Akira, 2009) and nucleotide-binding oligomerization domain receptors (Li et al., 2008).
DCs express a repertoire of PRR, allowing the
recognition of a range of pathogen constituents. The engagement of PRR on DCs leads to
de novo transcription and secretion of cytokines and chemokines, enhanced antigen presentation capacity, and migration to lymphoid
tissues where the DCs interact with T cells and
B cells to initiate and shape the adaptive immune response. The type of stimulus conditions DCs to adopt a Th1- or Th2-polarizing
function (Mazzoni and Segal, 2004; Kwissa et al.,
2007). However, many cell types, including
© 2009 Longhi et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months
after the publication date (see http://www.jem.org/misc/terms.shtml). After six
months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).
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helicase MDA5, resulting in activation of IRF-3 and representing a major pathway for the production of type I IFNs in a
TLR-independent fashion (Kato et al., 2006). Poly IC is a
strong inducer of type I IFN. Although DCs and macrophages
produce type I IFN upon poly IC stimulation in vitro, many
nonhematopoietic cell types potentially could provide a source
of this cytokine in vivo (Alexopoulou et al., 2001; Gitlin et al.,
2006). In addition, the critical question of whether type I IFN
is required for the adjuvant effect of poly IC and its mechanism
of action in situ has not been addressed.
In this paper, we study the mechanism whereby poly IC
adjuvants CD4+ Th1 immunity for an HIV gag protein vaccine
that is targeted in vivo to DCs within a monoclonal antibody
to the uptake receptor DEC-205/CD205 (Trumpfheller
et al., 2008). We found that poly IC is a superior adjuvant
and then we made several findings on its effects in vivo. First,
type I IFN is the dominant driver of two innate cellular
responses: the maturation of DCs and the activation of NK
cells to produce type II IFN. Second, type I IFN must act
directly on DCs to induce their maturation into immuno
stimulatory cells and also is necessary for the generation of
a Th1 CD4+ adaptive T cell response, whereas IL-12 and
type II IFN-R are not. Third, both bone marrow–derived
and stromal cells play essential roles in providing type I IFN.
These data illustrate that poly IC adjuvants Th1 CD4+ T cell
immunity by replicating the early systemic effects of viral
infection through its superior and widespread induction of
type I IFN.
RESULTS
Poly IC is a superior adjuvant for CD4+ T cell responses
to a protein vaccine
We had previously shown that poly IC was a superior adjuvant to monophosphoryl lipid A for inducing strong protective CD4+ T cell responses to HIV gag p24 delivered within
an anti-DEC antibody (Trumpfheller et al., 2008). To find the
most appropriate adjuvant for this new approach to proteinbased vaccines, we extended our analysis to other TLR ligands,
including MALP-2 (TLR2/TLR6), Pam3Cys (TLR1/TLR2),
poly IC (TLR3), poly ICLC (TLR3-complexed poly IC with
carboxymethylcellulose and poly-l-lysine to improve resistance to ribonucleases), LPS (TLR4), R-848 (TLR7/TLR8)
delivered as an aqueous compound or within a topical cream,
and CpG (TLR9). Mice were immunized with -DEC-gag
p24 mAb and specific adjuvants twice i.p. over 4 wk. 1 wk
after the final injection, antigen-specific responses were evaluated by IFN- secretion in response to gag p24 peptides,
primarily by multicolor flow cytometry.
Poly IC, together with its analogue poly ICLC, induced
stronger gag-specific CD4+ T cell responses compared with
the other adjuvants (Fig. 1, A and B) with frequencies of >1%
of IFN- producing CD3+CD4+ T cells after i.p. injection.
The improved CD4+ T cell responses with poly IC and poly
ICLC were also evident at the single cell level when IL-2 and
TNF- were measured (Fig. S1). ELISA assays showed that
IL-4 and IL-17 were not induced during the adjuvant role of
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nonhematopoietic cells, express PRR and produce cytokines
during innate immunity (Nolte et al., 2007). To understand
adjuvant action, it will likely be necessary to understand the
contribution of cytokines and different cellular sources of
cytokines to the initiation of immunity from the naive polyclonal repertoire.
Among innate inflammatory cytokines, type I IFNs are
considered to be major players for linking innate to adaptive
immunity. First uncovered for their innate antiviral activity
(Nagano and Kojima, 1954; Lindenmann et al., 1957), type I
IFNs also enhance adaptive responses. They activate DCs, critical antigen-presenting cells for initiating immunity (Blanco
et al., 2001), by promoting the expression of costimulatory
molecules (Luft et al., 1998; Gallucci et al., 1999; Ito et al.,
2001). This includes human blood monocytes, where type I
IFN can stimulate differentiation into DCs (Paquette et al.,
1998; Santini et al., 2000). Type I IFN–treated DCs prime T
cells in vitro more effectively. The DCs also up-regulate expression of lymph node–homing CCR7 and exhibit stronger
migratory capacity compared with DCs differentiated with
other cytokines (Paquette et al., 1998; Parlato et al., 2001).
Type I IFN further promotes cross-priming of CD8+ T cells
by direct stimulation of DCs (Le Bon et al., 2003). Le Bon
et al. (2001) showed that type I IFNs act on ex vivo–derived
DCs to become better stimulators of antibody immunity.
Nevertheless, the effects of type I IFN on DCs in situ need
definition to understand the link between the innate production of cytokines to adaptive immunity.
Type I IFNs also have direct effects on T cells, particularly CD8+ T cells (Tough et al., 1996), by extending their
survival during antigen-driven clonal expansion (Kolumam
et al., 2005; Le Bon et al., 2006). In contrast, the importance
of type I IFNs in the generation of antigen-specific CD4+
T cell responses is uncertain. Type I IFN inhibits secretion of
Th2 cytokines (IL-4 and IL-5) and stimulates type II IFN or
IFN- production (Brinkmann et al., 1993; Wenner et al.,
1996). Type I IFNs inhibit the death of activated CD4+
T cells (Marrack et al., 1999), a finding which was later
extended to the adoptive transfer of antigen-specific CD4+
T cells lacking the expression of type I IFN receptors (HavenarDaughton et al., 2006). However, although it was originally
believed to induce STAT4 activation, type I IFN failed
to promote Th1 commitment in human and mouse CD4+
T cells in vitro. Despite induction of detectable STAT4 tyrosine phosphorylation, the activation was transient and insufficient to drive Th1 development in the absence of IL-12
(Berenson et al., 2004; Ramos et al., 2007). Therefore, the
effect of type I IFNs on the generation of antigen-specific
CD4+ T cells in vivo is unclear from these observations.
Several TLR agonists are currently being evaluated as adjuvants for vaccine development. Among them, synthetic double-stranded RNA, polyinosinic:polycytidylic acid (poly IC),
induces inflammation and long-lasting T cell immunity (Salem
et al., 2006; Trumpfheller et al., 2008; Stahl-Hennig et al.,
2009). Poly IC is recognized by TLR3 located mostly in endosomal membranes. Also, poly IC binds the cytoplasmic RNA
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poly IC or poly ICLC, verifying a polarized Th1 response
(Fig. 1 C). The second most active adjuvant was R-848 applied in a cream to the skin, but the other adjuvants were

weak (Fig. 1, A and B). To verify the activity of the adjuvants,
we also measured antibody responses to HIV gag and found
that all the adjuvants were active, with LPS being at least as
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Figure 1. Poly IC is a superior adjuvant to elicit CD4+ T cell immunity. (A) CxB6 F1 mice were primed and boosted 4 wk apart with 5 µg -DEC-p24
and 50 µg poly IC, 50 µg Pam3cys, 0.5 µg Malp2, 50 µg poly ICLC, 10 µg LPS, 50 µg CpG, or R-848 cream. R-848 cream was applied topically over 5 cm2
on the back of shaved mice. IFN- secretion in gated CD3+CD4+ splenic T cells in response to HIV gag p24 peptides was measured 1 wk after boost. (B) As
in A, but means ± SD from five (poly IC), three (poly ICLC, R-848, and CpG), and two (Malp-2, Pam3cys, and LPS) experiments, with three mice per group.
(C) CxB6 F1 mice were primed and boosted 4 wk apart with 5 µg -DEC-p24 and 50 µg poly IC. 1 wk after boost, bulk splenocytes were stimulated with
gag p24 peptide mix or control peptide mix for 3 d. The concentrations of the indicated cytokines and chemokines were measured in cell culture supernatants by luminex. Samples were acquired in duplicate and analyzed by ELISA. Bars represent the mean ± SD from two experiments (six mice total).
(D) Mice were immunized as in A. 1 wk after boost, gag-specific antibodies in serum samples were measured by ELISA. Data are given as OD mean ± SD
from two independent experiments (five mice total).
JEM VOL. 206, July 6, 2009
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active as poly IC (Fig. 1 D). These results encouraged us to
compare the innate response to poly IC relative to other agonists to help explain its superior adjuvant role in inducing
Th1 type CD4+ T cell immunity.

Poly IC induces activation of DCs
Poly IC matures both mouse and human DCs (Verdijk et al.,
1999; Blanco et al., 2001; Lopez et al., 2004; Tsujimoto, 2006),
and this maturation was shown to depend on type I IFN
(Honda et al., 2003). However, these experiments were performed in vitro. To assess DC maturation in vivo, mice were
injected with 50 µg poly IC, and the effect of type I IFN was

Direct IFNAR signaling is critical for DC activation in vivo
To determine if type I IFN had to act directly on DCs to
bring about maturation, we made mixed bone marrow chimeras in which the injected bone marrow suspension was a
50:50 mixture of CD45.1 WT and CD45.2 IFN-AR/
cells (Fig. 4 A). When poly IC was given to these chimeric
mice, only the CD45.1 WT cells were able to up-regulate
costimulatory molecules and MHC class II (Fig. 4 B) and exhibit enhanced MLR stimulatory activity (Fig. 4 C and Fig. S3).
Therefore, Type I IFN directly promotes maturation of DCs
to link innate to adaptive immunity.

Figure 2. Induction of inflammatory cytokines in the serum by TLR ligands. Mice were treated i.p. with 50 µg poly IC, 50 µg Pam3cys, 0.5 µg
Malp2, 10 µg LPS, 50 µg poly ICLC, 50 µg CpG, and 5 cm2 of 0.2% R-848 cream. IL-6, TNF-, IL-12p40, IFN-, IFN-, and IFN- were analyzed in serum at
different time points (means of four mice). Error bars indicate the mean ± SD. Data are representative of two similar independent experiments.
1592
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The innate response to poly IC uniquely leads to high levels
of serum type I IFN
To assess the innate response to poly IC and poly ICLC, we
studied the systemic release of inflammatory cytokines, a prototype response to agonists for PRR. We did ELISA assays on serum at 1, 3, 6, or 20 h after administration of different TLR
ligands i.p., measuring IL-6, TNF-, IL-12p40, IFN-, IFN-,
and IFN-. All TLR agonists, to different extents, induced production of IL-6, TNF-, and IL-12 p40 (Fig. 2), whereas serum
IL-12p70, IL-1, and IL-10 were not detected (not depicted).
Interestingly, production of type I and type II IFNs was more restricted, being detected primarily with poly IC, poly ICLC, and
R-848. Detection of IFN- and IFN- was transient, peaking
at 3–6 h, and was highest with both poly IC and poly ICLC
(Fig. 2). Thus, strong type I IFN production is a special feature of
poly IC, suggesting a role for IFN in its adjuvant effect.

blocked by simultaneous injection of IFNAR1 (anti–IFN-
receptor) antibody or isotype control. After 12 h, expression
of MHC-II and costimulatory molecules (CD40 and CD86)
on DEC+ and DEC DCs was analyzed by flow cytometry
(Fig. 3 A). Blocking type I IFN receptor effectively reduced
DC maturation, as monitored by the up-regulation of these
immunostimulatory molecules in response to poly IC.
To directly evaluate the stimulatory capacity of DCs after
poly IC stimulation with or without blockade of type I IFN
receptors, we isolated the CD11c+ DC fraction from the
spleen, fixed the cells with formaldehyde to block further
differentiation in culture, and added the DCs in graded doses
to allogeneic T cells in an MLR. DCs from poly IC–treated
mice became active stimulators of the allogeneic MLR,
whereas blockade of type I IFNs abrogated this effect (Fig. 3 B),
showing that this cytokine was essential for DC maturation in
response to the poly IC adjuvant.
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(Walzer et al., 2005). In concordance with previous studies,
poly IC failed to directly activate mouse NK cells (Fig. 5 C).
We then considered that NK activation was indirect and a
result of stimulation by type I IFNs. To test this, mice were
injected with poly IC 1 h after injection of anti-IFNAR1 or
isotype control. Antibody treatment dramatically reduced
IFN- production by NK cells (Fig. 5 D). Collectively, these
results highlight the importance of type I IFN during the innate responses of both DCs and NK cells in the intact animal.
Poly IC directly activates multiple cell types to produce
type I IFN
Type I IFNs are rapidly produced by many cell types in response to immune and/or inflammatory stimuli. Poly IC was
previously shown to stimulate mouse conventional DCs (cDCs),
bone morrow–derived DCs, and macrophages to produce

Figure 3. Type I IFN signaling controls DC maturation. (A) 1 h after 100 µg of anti-IFAR1 blocking antibody or isotype control, mice were stimulated
with 50 µg poly IC for 12 h and analyzed for cell surface MHC-II, CD86, and CD40 on DEC+ and DEC DCs. (B) As in A, but graded numbers of fixed splenic
DCs from BALB/C mice were added for 5 d to 2 × 105 allogeneic C57BL/6 T cells. T cell proliferation was detected by CFSE dilution of CD3+ cells. Data are
representative of three experiments.
JEM VOL. 206, July 6, 2009
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Poly IC induces IFN- production by NK cells
An additional component to the innate response to the in vivo
administration of poly IC is the rapid activation of NK cells to
produce IFN- (Salem et al., 2006). Because we had observed
an innate IFN- response to poly IC, we assessed NK cells as
a possible source. We found that CD11cintDX5+ NK cells
were major producers of IFN-, whereas other cells, including CD11chighDX5 DCs were inactive (Fig. 5, A and B).
Human NK cells respond directly to poly IC and CpG to
produce IFN- (Lauzon et al., 2006) but, in contrast, purified
mouse NK cells fail to respond directly to TLR agonists and
require the presence of DCs or IL-12 (Sawaki et al., 2007). To
assess the latter possibility, highly purified splenic NK cells
were incubated overnight in the presence of poly IC, and
IFN- production was measured by ELISA. As a positive control, the NK cells were stimulated with rIL-12 and rIL-15

Although production of type I IFN by pDCs requires activation of the TLR system, cDCs and fibroblasts were shown
to secrete type I IFNs in response to viral infection in a cytosolic helicase-dependent fashion (Kato et al., 2005). Because
poly IC can be recognized by the RNA helicase mda5, we
next tested if poly IC–induced IFN- required this PRR.
Monocytes, DEC+ DC, and stromal cells from WT, mda5/,
or TLR3/ mice were stimulated in vitro with poly IC as described in the previous paragraph. Interestingly, the production
of IFN- by all cell types was comparable between WT and
TLR3/ cells, whereas it was severely impaired in mda5/
cells (Fig. 6 C). Similar results were obtained when we measured the release of type I IFN into the serum of mice genetically deficient in these PRRs after poly IC injection (Fig. S2),
confirming prior observations (Gitlin et al., 2006). DEC+ DCs
were also able to produce small amounts of IFN- in an mda5independent fashion (Fig. 6 C), but this was ablated in mice
doubly deficient in TLR3 and mda5 (not depicted).
To investigate the extent to which type I IFN in vivo required hematopoietic cells, e.g., DEC+ DCs and monocytes,
and nonhematopoietic cells, e.g., endothelia, stromal bone
marrow chimeras were generated by reconstituting mda5/
mice with WT bone marrow or, alternatively, WT mice

Figure 4. Direct type I IFN signaling of DCs is required for their maturation. Mixed bone marrow chimeras were prepared with a 50:50 mixture of
bone marrow from WT (CD45.2) and IFNAR/ (CD45.2+) mice. (A) Gating strategy for WT (CD45.2) and IFNAR/ (CD45.2+) DCs 4–6 wk after chimerism. (B) The chimeras were stimulated with 50 µg poly IC or PBS for 12 h. Expression of CD86, MHC-II, and CD40 on WT and IFNAR/ DCs, was analyzed
by FACS. Arrows show increased up-regulation of costimulatory molecules in IFNAR/ DCs. (C) The chimeras were stimulated as in B. After CD11c enrichment, WT and IFNAR/ CD11chi were FACS sorted as in A. Graded numbers of fixed B6.WT or B6.IFNAR/ splenic DCs were added for 5 d to 2 × 105
allogeneic Balb/C T cells. T cell proliferation was detected by CFSE dilution of CD3+ cells. Cells numbers are indicated as 103. Data are representative of
two similar independent experiments.
1594
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type I IFN (Gitlin et al., 2006; Kumagai et al., 2007). Splenic
cells were sorted into several different cell types, stimulated in
vitro with poly IC, and tested for the production of type I IFN.
First, spleen cells were preenriched by magnetic depletion
of B, T, and erythroid cells with antibodies to CD19, CD3, and
TER119. The depleted cells were then sorted based on the
expression of a set of specific markers. NK cells were CD3DX5+,
plasmacytoid DCs (pDCs) were CD11cintDX5B220+, and
cDCs were CD11chiDX5CD8 or CD8+DEC-205+ (Fig. 6 A;
Asselin-Paturel et al., 2005; Blasius et al., 2007; Dudziak
et al., 2007). To sort granulocytes and monocytes, we gated for
CD11bhi cells and then isolated LyC6hi granulocytes and CD115+
monocytes. Macrophages were defined as CD11blowF4/80+
cells (Fig. 6 A; Taylor et al., 2005; Randolph et al., 2008).
When each of the sorted cell subsets (3 × 105 cells/well)
were stimulated overnight with poly IC, both CD8+DEC+
DCs and monocytes produced type I IFN, whereas CD8
DCs, pDCs, NK, granulocytes, and macrophages did not
(Fig. 6 B). To test the capacity of nonhematopoietic cells to
produce IFN-, we used splenic stromal cells (105 cells/well)
that had been expanded from CD45-negative spleen cells.
Similar to monocytes and DEC+ DCs, stromal cells were able
to produce type I IFN (Fig. 6 B).
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were reconstituted with mda5/ marrow. The different chimeras were injected i.p with poly IC, and serum was collected after 6 h. Interestingly, WT recipients of mda5/
marrow produced high levels of IFN-/, whereas mda5/
recipients of WT marrow were severely compromised
(Fig. 6 D). These data demonstrated that stimulation of radioresistant cells, but not bone marrow–derived cells, was required for
the bulk of type I IFN production after poly IC treatment.

IFN from both bone marrow–derived and nonhematopoietic
cells is needed for the adjuvant function of poly IC
Because mda5 and TLR3 are the major PRRs for type I IFN
production in response to poly IC, and both receptors
were needed to induce gag-specific CD4+ T cell responses
(Trumpfheller et al., 2008), we analyzed chimeric mice in which
either the bone marrow donor or recipient were lacking both
mda5 and TLR3. The B and T cells in these mice were >98%
donor in origin after typing with anti-CD45.1 and antiCD45.2 (unpublished data). In each case, i.e., when either
the hematopoietic cells or nonhematopoietic cells could not

Figure 5. NK cells are major producers of IFN- after poly IC. Mice were injected i.p. with 50 µg poly-IC or PBS. After 2 h, spleens were collected and a
single cell suspension of splenocytes was incubated with 10 µg/ml BFA for 3 h before intracellular staining for IFN-. (A) Five color flow cytometry to identify
IFN-–positive splenocytes. (B) As in A, but production of IFN- by NK cells gated as CD3 DX5+ cells. Means ± SD of four experiments. (C) Highly purified
CD3 DX5+ NK cells. 3 × 105 cells/well were stimulated with 50 µg/ml poly IC or, as a positive control, a combination of rIL-12 and rIL-15. After 12 h, IFN- in
culture supernatants was detected by ELISA. Means ± SD of three independent experiments are shown. (D) Mice were injected with poly IC and anti-IFAR1
blocking antibody or isotype control. Production of IFN- was detected by intracellular staining. Mean ± SD from three experiments is shown.
JEM VOL. 206, July 6, 2009
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Production of type I IFNs by poly IC, but not IL-12 p40,
is needed for Th1 immunity
To determine if type I IFN could influence the development of
adaptive Th1 immunity, we first analyzed gag-specific CD4+ T
cells responses after IFNAR1 blocking of mice immunized with
either -DEC-p24 or nontargeted gag p41 protein. In both
cases, the adjuvant effect of poly IC was markedly reduced by
IFNAR1 blocking compared with isotype control (Fig. 7 A and
Fig. S4 A). TNF- and IL-2 production likewise was also
severely reduced (unpublished data). Similar results were obtained with IFNAR/ mice, which were unable to develop
adaptive Th1 immunity in response to -DEC-p24 plus poly
IC (Fig. 7 B). To extend the evidence for a critical role of type
I IFNs, we studied mice with a genetic deletion of STAT1, the
major signal transducer for type I IFNs. As anticipated, immunization with either -DEC-p24 or p41 protein was totally ablated
in STAT1/ mice (Fig. 7 C and Fig. S4 B). Thus, the stimulation of type I IFNs by poly IC is required for its adjuvant role.

Type I IFNs may regulate Th1 responses by indirect
mechanisms. IFN- signaling can up-regulate IFN- production by DCs, promoting the ability of naive T cells to respond to IL-12 (Wenner et al., 1996; Montoya et al., 2002),
whereas type I IFN can up-regulate expression of IL-12R2
on human CD4+ T cells, increasing responsiveness to IL-12,
a pivotal cytokine for Th1 responses (Rogge et al., 1997). To
determine if type I IFN might additionally require either increased IFN- or IL-12 signaling, CD4+ T cell responses to
DEC-p24 and poly IC were analyzed in IFN-R (IFN- receptor) and IL-12 p40–deficient mice. Both IFN-R/ and
IL-12p40/ mice mounted similar responses to WT mice
(Fig. 7, D and E and Fig. S4, C and D), implying that type I
IFN, but not type II IFN or IL-12, was directly required for
poly IC to induce polarized Th1 immunity.

make type I IFN via poly IC, its adjuvant effect was reduced
by >80% (Fig. 8). These results indicate that a systemic innate
response, and not only a local response by antigen-capturing
DCs, accounts for the adjuvant role of poly IC.

Figure 6. Production of IFN- by multiple cell types. (A) Splenocytes from WT mice were depleted with Ter119, CD3, and CD19 biotinylated
antibodies using streptavidin magnetic beads before cell sorting. For monocytes, macrophages, and granulocytes, splenocytes were additionally depleted
of DX5+ cells. cDCs (CD3DX5CD11chiCD8 and CD8+DEC205+), pDCs (CD3DX5CD11clowB220+), NK cells (CD3DX5+), macrophages (CD11blowF4/80+),
monocytes (CD11bhiCD115+), and granulocytes (CD11bhiLy6G+) were sorted based on their expression of specific markers (see text). Numbers 1–6 indicate
the different cell types sorted. (B) Highly purified cells were plated at 3 × 105 cells/well in a round-bottomed 96-well plate and incubated with 50 µg/ml
poly IC or medium alone. Splenic stromal cells, obtained as described in the Materials and methods, were plated at 5 × 104 cells/well in a 48-well plate.
Supernatants were collected after 12 h and production of Type I IFN was detected by ELISA. (C) As in B, DEC+ DCs, monocytes, stromal cells from WT,
TLR3, and mda5-deficient mice were stimulated in vitro with 50 µg/ml poly IC or medium alone. (D) WT and mda5/ mice were lethally irradiated and
injected with bone marrow cells from WT or mda5/ mice. After 6 wk, chimeras were injected with 50 µg poly IC. Serum was collected 6 h later and analyzed by Type I IFN ELISA kit. Error bars show the means ± SD from at least two experiments. ND, not detectable.
1596
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DISCUSSION
Poly IC as a clinically feasible adjuvant for proteinbased vaccines
Vaccines, particularly those that elicit protective T cell immunity,
are comprised of antigens and adjuvants, with the latter influencing the quantity and quality of the specific immune response.
Vaccine science can be extended by understanding the mechanism of adjuvant action, particularly in the setting of the intact

animal and a polyclonal T cell repertoire. In this paper, we have
analyzed the adjuvant mechanism of poly IC in an experimental
system in which HIV gag is the antigen and the elicited immune
response is durable, broad (many peptides recognized), and capable of providing protective immunity (Trumpfheller et al., 2008).
In contrast to the findings in the current paper, many prior studies
of adjuvants, like CpG and LPS, have analyzed isolated cells and
the clonal expansion of TCR transgenic T cells (Lore et al., 2003;
Napolitani et al., 2005; Thompson et al., 2005; He et al., 2007;
Mata-Haro et al., 2007).
Our interest in poly IC was initially based on two sets of
findings. Poly IC has been used in humans to induce type I
IFN in cancer patients and had a good safety record (Robinson
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et al., 1976). These studies were directed purely to the innate
IFN response, rather than adjuvanting adaptive Th1 immunity. Also, Stahl-Hennig et al. (2009) have shown that poly
IC is a more potent adjuvant than other agonists for responses
to protein antigens in rhesus macaques. We find that poly IC
is superior to several other candidate adjuvants and have
identified important mechanistic aspects. For example, although both monocytes and DEC+ DCs are able to make
type I IFN in response to poly IC, we found in bone marrow
chimera experiments that the main source of type I IFN in

vivo after administration of poly IC emanates from non
hematopoietic radioresistant cells. We proceeded to analyze the
contribution of the type I IFN response to adjuvant action.
Type I IFN but not type II or IL-12 p40 mediates
the adjuvant action of poly IC
A recognized feature of adjuvants is the induction of inflammatory cytokines through PRR (Kool et al., 2008; Li et al., 2008).
We find that one type of cytokine, type I IFN, dominated the
adjuvant role of poly IC during CD4+ Th1 immunity in vivo.
Downloaded from http://rupress.org/jem/article-pdf/206/7/1589/825651/jem_20090247.pdf by Rockefeller University user on 18 August 2020

Figure 7. The adjuvant role of poly IC is dependent on type I IFNs and independent of IL-12 p40. (A) CxB6 F1 mice were injected i.p. with 5 µg
-DEC-p24 or 10 µg gag-p41 and 50 µg poly IC together with anti-IFNAR1 or isotype control. Mice were boosted with the same conditions at 4 wk. 1 wk
later, HIV gag-specific CD3+ CD4+ splenic T cells were analyzed for IFN-. (B–E) As in A, the percentage of CD3+ CD4+ T cells producing IFN- was measured in WT, IFNAR/, STAT-1/, IFN-R/, and IL-12 p40/ immunized mice, respectively. Means ± SD are shown of two independent experiments
with a total of six mice. ***, P = 0.001.
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rather than bacteria and parasites, and does not require the
presence of IL-12 for the induction of Th1 immunity.
Type I IFN activates NK cells to produce type II IFN in vivo,
but the latter is not required for the adjuvant action
of poly IC
Another major pathway to Th1 immunity involves NK cells.
NK cells are rapidly recruited to lymph nodes and splenic white
pulp upon stimulation with mature DCs or some adjuvants like
R-848 and poly IC, providing an early source of IFN-
required for Th1 polarization (Martin-Fontecha et al., 2004;
Grégoire et al., 2008). In addition, the production of proinflammatory cytokines by NK cells has been associated with the
adjuvant effect of poly IC (Salem et al., 2006). Specifically,
engagement of NKp30 by DC induces secretion of proinflammatory cytokines by NK cells, e.g., TNF-, which has been
identified as an active inducer of DC maturation (Vitale et al.,
2005). NK cells may have additional roles in inducing DC maturation, e.g., by direct cell contact and by selective killing of
mature DCs that do not express optimal levels of MHC class I
molecules (Ferlazzo et al., 2001). Several inflammatory cytokines
stimulate NK cell proliferation and IFN- production. For example, IL-12 synergizes with IL-18 or IL-15 to induce IFN-,
whereas IFN- promotes NK proliferation and cytotoxicity
(Okamura et al., 1995; Yoshimoto et al., 1998; Fehniger et al.,
1999; Kim et al., 2000; Chakir et al., 2001). In this paper, we
have found that poly IC induces strong IFN- production by
NK cells and that this is fully dependent on the production of
type I IFN in vivo by direct NK stimulation or though synergism
with other cytokines, i.e., IL-18 (Matikainen et al., 2001). Yet
IFN- was not needed for CD4+ Th1 responses or DC maturation, which was normal in mice genetically lacking IFN- receptor. It remains possible that NK cells serve other roles in the
adjuvant effects of poly IC, i.e., independent of type II IFN.

Figure 8. Both hematopoietic and nonhematopoietic cells contribute to the adjuvant effect of poly IC. (A) Gag p24-specific CD4+ T cell responses were evaluated in bone marrow chimeras. WT and double TLR3.mda5/ mice were lethally irradiated and injected with bone marrow cells from
WT or deficient mice. After 6 wk, chimeras were primed and boosted 4 wk apart with 5 µg -DEC-p24 and 50 µg poly IC. After 1 wk, HIV gag-specific
CD3+CD4+ splenic T cells were analyzed for IFN- secretion. Means ± SD from two experiments are shown; n = 6. (B) Chimerism was assessed by expression of mda5 on CD11c+ splenic cells. ***, P = 0.001.
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Although type I IFN has been proposed to have a role during
clonal expansion and survival of CD8+ T cells, its role in CD4+
Th1 development was unclear (see Introduction). However,
prior experiments were done in vitro with recombinant cytokines and using CD3 antibody stimulation or transgenic models, making it difficult to extrapolate in vivo. We did consider
the possibility that type I IFN could act indirectly by promoting secretion of other Th1-enhancing cytokines, IL-12 and
IFN-. IL-12 plays a crucial role in Th1 priming (Trinchieri,
1994), whereas IFN- increases responsiveness to IL-12 and, in
addition, activates the Th1-specific transcription factor T-bet
(Lighvani et al., 2001; Afkarian et al., 2002). Nevertheless, our
findings in vivo show that deletion of IL-12 p40 or IFN- receptor genes did not abrogate the CD4+ T cell response to a
protein plus poly IC vaccine, which predominantly depends on
type I IFN to be an adjuvant.
The relevance of IL-12 in vivo seems to depend on the
nature of the infecting or immunizing agent. IL-12 is a major
cofactor for Th1 differentiation during infection with several
bacteria and parasites (Gazzinelli et al., 1994; Cooper et al.,
1997) as well as soluble antigens together with adjuvant, e.g.,
MPLA, Quil A, and CpG (Magram et al., 1996; Smith et al.,
1999; Puggioni et al., 2005; Iborra et al., 2008). Yet for some
virus infections, e.g., lymphocytic choriomeningitis virus and
mouse hepatitis virus, the lack of IL-12 has little or no effect
on the induction of Th1 immunity (Schijns et al., 1998;
Oxenius et al., 1999). One criterion for the selection of a
suitable Th1 adjuvant has been the production of IL-12 by
DCs in vitro, in particular, when searching for synergistic effects of multiple TLR ligands (Napolitani et al., 2005). In
contrast, we could not detect systemic production of IL-12
p70 after administration of poly IC, whereas poly IC was superior at inducing systemic type I IFNs. Our findings indicate that poly IC mimics infections with certain viruses,
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Both bone marrow–derived and nonhematopoietic cells
need to respond to poly IC
Elegant studies have shown that antigen-presenting cells must
themselves respond to TLR agonists to induce strong clonal
expansion of antigen-specific TCR transgenic T cells (Spörri
and Reis e Sousa, 2005; Nolte et al., 2007), but the response
of naive mice and the contribution of radioresistant cells was
not fully evaluated. Unexpectedly, we found that the adjuvant role of poly IC for a primary CD4+ T cell response was
severely reduced when either bone marrow–derived or radioresistant cells lacked the mda-5 and TLR3 PRRs. Radioresistant cells could include endothelial, epithelial, and stromal
cells. The Langerhans type of DC is also radioresistant (Merad
et al., 2002), but we found that depletion of these cells did
not alter the levels of type I IFN detected in the serum. In
contrast, we showed that stromal cells in vitro produced type
I IFN as effectively as DCs upon poly IC stimulation, and in
ongoing experiments, we find that poly IC markedly increases type I IFN mRNA in liver and lung cells suspensions
that are depleted of CD11c+ cells. These findings indicate
JEM VOL. 206, July 6, 2009

that adjuvants become more effective when they induce a
systemic inflammatory response during the time that the antigen is captured and presented by DCs. In experiments that
were not published, we found that the Th1 response was reduced if the administration of poly IC either preceded or followed the administration of protein antigen by 6 h. The
systemic production of type I IFNs enhances two key innate
responses in vivo: the maturation of DCs and the activation
of NK cells, as well as key adaptive lymphocytes mediating
delayed type hypersensitivity (Gallucci et al., 1999), humoral
immunity (Le Bon et al., 2001), and CD8 T cell memory
(Ferrantini et al., 1994). The further development of adjuvants may well need to consider the contributions of both
hematopoietic and nonhematopoietic cells, which make innate cytokines that work directly on DCs so that they can act
as initiators of antigen-specific adaptive immunity.
Materials and methods
Mice. C57BL/6, BALB/c, and CxB6 F1 were obtained from Harlan,
129/SvJ, IFNR/, and IL-12 p40/ were obtained from The Jackson
Laboratory, STAT1/ were provided by D. Levy (New York University,
NY, NY), IFNAR/ were provided by K. Murali-Krishna (University of
Washington, Seattle, WA), and TLR3/ were provided by S. Akira (Osaka
University, Osaka, Japan). Mice were maintained under specific pathogen-free
conditions and used at 7–8 wk of age according to Institutional Animal Care
and Use guidelines. Animal protocols were approved by the Institutional
Animal Care and Use Committee (IACUC).
In vivo cytokine secretion. Mice were injected i.p. with 50 µg poly IC
(InvivoGen), 50 µg Pam3cys (InvivoGen), 0.5 µg Malp2 (Enzo Biochem,
Inc.), 10 µg LPS (E. Coli; Sigma-Aldrich), 50 µg poly ICLC (Oncovir, Inc.),
50 µg CpG ODN1826 (InvivoGen), or R-848 cream (2% topically applied
to 5 cm2 of back skin; Celldex Therapeutics, Inc.), and serum was collected at the indicated times. Production of TNF-, IL-12p40, IL-12p70,
IL-6, IFN- (eBioscience), and IFN- and IFN- (R&D Systems) was
determined by ELISA according to the manufacturer’s instructions.
Cell sorting and stromal cell isolation. Spleens were cut in small pieces
and incubated at 37°C for 30 min in Hank’s medium supplemented with
400 U/ml collagenase d (Roche). EDTA (5 mM in final concentration) was
added for the last 5 min. Cells were stained with biotinylated anti-CD3, antiCD19, and anti-Ter119 mAbs (BD) for 20 min, washed, incubated with
Streptavidin-coated magnetic beads, and passed through LD columns (Miltenyi
Biotec). The negative fraction was collected and stained with Live/Dead
Fixable Aqua viability dye (Invitrogen), FITC–anti-DX5, PE–anti-CD11c,
PercPCy5.5-B220, Pacific Blue–anti-CD3, Alexa Fluor 750–anti-CD8
(eBioscience), and Alexa Fluor 647–DEC-205 (produced in house). Alternatively, cells were stained with Fixable Aqua viability dye, FITC–anti-Ly6G,
PE–anti-CD115, PerCP–anti-F4/80, PE-Cy7–anti-CD11c, and Alexa Fluor
750–CD11b (eBioscience). Different populations were isolated by sorting on
a FACSAria with DiVa configuration (BD). Splenic stromal cells were obtained as previously described (Cheng et al., 2007). In brief, spleens were cut
into small fragments, placed in a 48MW plate, and cultured in RPMI 1640
medium supplemented with 20% FCS and 1% MEM nonessential amino
acids. After 1 mo, cells were further purified by CD45 negative selection.
ELISA for antibody response. To detect gag-specific antibody, highbinding ELISA plates (BD) were coated with 1 µg/ml of gag protein overnight at 4°C, washed with PBS/0.1% Tween 20, and blocked with PBS/5%
BSA for 1 h at 37°C. Serial dilutions of serum were added to the plates and
incubated for another 1 h at 37°C. Plates were washed and incubated 1 h at
37°C with secondary HRP goat anti–mouse IgG antibody (Jackson Immuno
research Laboratories). TMB (3,3,5,5-tetramethylbenzidine) substrate
1599
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Innate type I IFNs in vivo induce DCs to stimulate
adaptive immunity
The major challenge to understanding adjuvant function in
vivo is, by definition, to understand the induction of adaptive
immunity and how an early innate response to an adjuvant
leads to adaptive immunity. Immunity induced by vaccination
requires two broad functions at the level of DCs but needs to
be studied in vivo. One is antigen presentation, which we enhanced by targeting the HIV gag protein to the DEC-205
antigen uptake receptor on a subset of DCs. Nevertheless,
our mechanistic findings were similar when we administered
higher doses of the antigen as an isolated gag p41 protein. The
second function is that antigen-capturing DCs need to mature
in vivo to induce immunity, as shown initially with another
adjuvant, -galactosyl ceramide (Fujii et al., 2003). Additionally, maturation is required to avoid T cell tolerance upon targeting of antigens to DCs (Hawiger et al., 2001; Bonifaz et al.,
2002; Kretschmer et al., 2006; Yamazaki et al., 2008). Our experiments show that type I IFN is important for DC maturation after poly IC. Poly IC and type I IFNs were each known
to induce DC maturation, but their interdependence had not
previously been tested in vivo. Likewise, Le Bon et al. (2001)
found that type I IFNs could act on ex vivo–derived DCs,
which then stimulates antibody immunity. We noted that poly
IC not only up-regulates DC costimulatory molecules but allows DCs to become better inducers of MLR. The latter assay
remains valuable to document that DCs have matured in the
critical functional sense and not only by altering their cell surface phenotype. Both changes in DCs, i.e., up-regulation of
CD86 and increased MLR stimulation, were abrogated by
blockade of type I IFN receptors. Although ligation of PRRs
has previously been associated with some features of DC maturation, we showed that this is not sufficient by itself and, additionally, the development of immunostimulatory function
requires direct IFNAR signaling of the DCs.

solution (Thermo Fisher Scientific) was used as substrate. OD was measured
in an ELISA reader at 450 nm.

NK activation. 2 h after 50 µg poly IC i.p., spleen cell suspensions were
prepared and incubated for 3 h with 10 µg/ml brefeldin A (Sigma-Aldrich).
Cells were stained with Live/Dead Fixable Aqua viability dye, FITC–antiDX5, PE–anti-CD11c, and Pacific Blue–anti-CD3 mAbs. Cells were then
fixed, permeabilized, and stained with APC–anti–IFN- antibody. Sorted
NK cells (CD3DX5+) were cultured (3 × 105) with 50 µg/ml poly IC or
2 ng/ml rIL-12 and 1 ng/ml rIL-15 (eBioscience).
Bone marrow chimeras. Recipient mice were  irradiated twice with
500 rad, 3 h apart. 3 h later, they were reconstituted with 3 × 106 marrow
cells that had been harvested from the femurs and tibias of age-matched
mice. After 6 wk, mice were tested for chimerism by RT-PCR for mda5 on
CD11c+ cells (InvivoGen) or by flow cytometry, based on the expression of
CD45.1 and CD45.2 (>98%).
Assays for HIV-specific CD4+ T cells. Mice were immunized twice i.p. at
4-wk intervals with 5 µg HIV gag-p24 and 10 µg HIV gag-p41 (Trumpfheller
et al., 2008) together with adjuvant, which was 50 µg poly IC, 50 µg
Pam3cys, 0.5 µg Malp-2, 10 µg LPS, 50 µg poly ICLC, and R-848 cream
(topic, 5 cm2) or 50 µg CpG ODN1826. For IFNAR1 blocking, mice were
simultaneously injected days 0 and 2, with 100 µg of anti-IFNAR blocking
antibody or isotype control. 1 wk later, splenocytes were restimulated with
2 µM p24 or negative control peptide mix, along with 2 µg/ml of costimulatory -CD28 (clone 37.51) for 6 h. 10 µg/ml brefeldin A was added for the
last 5 h. Cells were washed, incubated 10 min at 4°C with 2.4G2 mAb to
block Fc receptors, washed, and stained with Live/Dead Fixable Aqua viability dye, Pacific blue–conjugated anti-CD3, PerCP-conjugated anti-CD4,
and Alexa Fluor 750–conjugated anti-CD8 mAbs for 20 min at 4°C. Cells
were permeabilized (Cytofix/Cytoperm Plus; BD) and stained with APC–
anti–IFN-, PE–anti–IL-2, and PE-Cy7 anti–TNF- mAbs for 15 min at
room temperature (BD). Samples were acquired on an LSR II flow cytometer and analyzed with FlowJo Software (Tree Star, Inc.).
Statistical analysis. Statistical significance was evaluated using a two-tailed
Student’s t test with a 95% confidence interval. Results are expressed as means
± SD. In the figures, p-values of 0.001 are labeled with a triple asterisk. Analysis was performed with a Prism 3 program (GraphPad Software, Inc.).
Online supplemental material. Fig. S1 shows the frequency of IL-2 and
TNF-–producing CD4+ T cells after DEC-p24 immunization with different adjuvants. Fig. S2 demonstrates the mda-5 dependence of the production of type I IFN in serum. Fig. S3 shows the gating strategy for the MLR
assays. Fig. S4 shows representative dot plots from Fig. 7.
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